Tibotec
Saved Wikipedia (April 17) for "Tibotec"
https://en.wikipedia.org/wiki/Tibotec
2023-04-17-wikipedia-org-tibotec.pdf
Industry : Pharmaceutical
Founded : 1994; 29 years ago
Founders :
Carine Claeys
Marie-Pierre de Béthune
Kurt Hertogs
Hilde Azijn
Defunct : 2002
Fate : Acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division
Website : tibotec.com
Tibotec was a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002.
In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceuticals) joined Tibotec. The company was acquired by Johnson & Johnson in April 2002.[1] The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).[2]
Darunavir (TMC114, tradename Prezista), a protease inhibitor
Etravirine (TMC125, tradename Intelence), a non-nucleoside reverse transcriptase inhibitor (NNRTI)
Bedaquiline (TMC207/R207910, tradename Sirturo), an diarylquinoline anti-tuberculosis drug[3]
Rilpivirine (TMC278, tradename Edurant), an NNRTI
Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.[4]
Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.
^ "Johnson & Johnson to Acquire Tibotec-Virco" (Press release). Johnson & Johnson. Mar 22, 2002.
^ Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Gelder, Jozef Van; Woestenborghs, Robert; Heykants, Jozef; Schellekens, Karel; Janssen, Marcel A. C.; Clercq, Erik De; Janssen, Paul A. J. (1990). "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives". Nature. 343 (6257): 470–474. Bibcode:1990Natur.343..470P. doi:10.1038/343470a0. PMID 1689015. S2CID 4354080.
^ Andries, K.; Verhasselt, P; Guillemont, J; Göhlmann, H. W.; Neefs, J. M.; Winkler, H; Van Gestel, J; Timmerman, P; Zhu, M; Lee, E; Williams, P; De Chaffoy, D; Huitric, E; Hoffner, S; Cambau, E; Truffot-Pernot, C; Lounis, N; Jarlier, V (2005). "A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis". Science. 307 (5707): 223–7. Bibcode:2005Sci...307..223A. doi:10.1126/science.1106753. PMID 15591164. S2CID 33219841.
^ Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2.
hide
Product
brands
Pharmaceuticals
Medtech
Consumer
healthcare
Companies
Subsidiaries
Pharmaceuticals
Tibotec
Medtech
Consumer
healthcare
Acquisitions
Partnerships
People
Executives
and scientists
Joaquin Duato (CEO)
Alex Gorsky (Executive Chairman)
Board of
directors
Founders
Ex-board
members,
executives,
and scientists
Former
subsidiaries
Legacy
brands
Benecol (US license)
Buildings
Related